 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...5051525354555657585960...235236» |
- Treatment and outcomes of pancreatic cancer in Armenia: Hospital-based study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5223;
As our results has shown survival of pancreatic cancer patients in Armenia is dismal, not exceeding 1 year. Hopefully further research in the field and new treatment modalities will improve the situation.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5214;
So far, no standard regimen is available and alkylating agents alone, such as temozolomide or in combination with 5-fluorouracil or capecitabine are widely used... Among the advanced well-differentiated neuroendocrine tumors, oxaliplatin based chemotherapy alone or plus bevacizumab could be a good alternative regimen, especially in pts with pNETs and G3 NETs.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5194;
P2
Based on the data from this study, a prospective, single-arm Phase II trial is planned. Clinical trial information: NCT05532319.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5152;
P2
HCC, especially in those with main portal trunk invasion. Clinical trial information: NCT05412589.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Zepsun (donafenib) / Suzhou Zelgen
Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5151;
P2
The enrollment and follow-up are continuing. Clinical trial information: NCT05166772.
- Zepsun (donafenib) / Suzhou Zelgen
Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody for unresectable hepatocellular carcinoma (uHCC): A retrospective analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5149;
Of 36 patients included in the analysis, all of them received first-line treatment of TACE (embolization of pirarubicin hydrochloride 40mg, iodized oil 10-20ml with or without gelatin sponge) plus HAIC (oxaliplatin 85 mg/m2 2h, leucovorin 400 mg/m2 1h, fluorouracil bolus 400 mg/m2 in the first 10 minutes, and fluorouracil infusion 2400 mg/m2 for 46h) combined with donafenib 200mg bid, anti-PD-1 antibody Q3W... Chemoembolization plus hepatic arterial infusion chemotherapy combined with donafenib, anti-PD-1 antibody are effective and tolerable for uHCC patients.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5132;
Study enrollment is ongoing, more mature data will be presented later. Clinical trial information: ChiCTR2200064384.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5128;
The differences in the initial TME of patients, especially in tumor-infiltrating T lymphocytes, may be potential biomarkers for predicting response and prognosis. This finding provides clues to search for biomarkers for the triple combination therapy of HAIC combined with lenvatinib and PD-1 inhibitors in advanced HCC.
- Zepsun (donafenib) / Suzhou Zelgen
Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, phase 2 study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5127;
Phase 3 study also showed the survival benefit of donafenib for unresectable HCC compared with sorafenib...Patients received FOLFOX HAIC (oxaliplatin 85 mg/m2 3h, leucovorin 200 mg/m2 2h, fluorouracil bolus 400 mg/m2 in the first 15 minutes, and fluorouracil infusion 2400 mg/m2 for 46 hours) Q3W plus donafenib 200mg bid, anti-PD-1 antibodies Q3W until disease progression or unacceptable toxicity, followed by multidisciplinary assessment and potential hepatectomy... A triple combination of donafenib, anti-PD-1 antibodies and HAIC is well tolerated and effective, it
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5125;
A triple combination of donafenib, anti-PD-1 antibodies and HAIC is well tolerated and effective, it Tislelizumab combined with lenvatinib and FOLFOX4-HAIC showed high conversion rate and acceptable toxicity in the treatment of middle-advanced stage HCC, suggesting that this combination could be considered as a new conversion strategy in this population.
- Zepsun (donafenib) / Suzhou Zelgen, AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
Hepatic artery infusion chemotherapy combined with donafenib and camrelizumab in patients with unresectable hepatocellular carcinoma presenting portal vein tumor thrombus: A prospective, single-arm study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5122;
Longer follow-up is required for further evaluation. Clinical trial information: ChiCTR2100051714.
- Costs and health care resource utilization (HCRU) for patients with advanced biliary tract (aBTC) cancer using administrative databases in Ontario, 2010 to 2020. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5101;
While cost results were stratified by type of BTC (AOV and non-AOV) and type of 1L therapies, the mean cost per patient ranged from $30,905 CAD to $44,190 CAD and HCRU results indicated substantial mean number of cancer clinic visits and inpatient hospitalizations. Thus, BTC patients incur a significant economic burden to the patients and Ontario public payer health system.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Toripalimab combined with fluorouracil, leucovorin calcium, oxaliplatin and irinotecan (FOLFIRINOX) regimen or combined with oxaliplatin and tegafur (SOX) regimen in perioperative treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma (G/GEJ): An open-label, randomized, phase II study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5083;
P2
There were no significant differences in efficacy and safety between the two groups. Whether intensive or simplified treatment is more suitable for neoadjuvant therapy needs to be further explored.
- Effect of overexpression of ERK1/2 and MDR1 on chemoresistance in advanced gastric cancer patients. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5051;
NACT group treated with docetaxel (60 mg/m2), oxaliplatin (85 mg/m2), leucovorin (200 mg/m2), and 5-fluorouracil (2,600 mg/m2 as a 24 hr infusion), all given on day 1 and administered every 2 weeks before surgery. ERK1/2 and MDR1 found to over-express in stage III, predicts the degree of resistance and MDR phenotype in the GC patients.
- 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5047;
No significant difference in survival outcome was observed between ICI and irinotecan-based chemotherapy as third-line treatment for patients with RMGC. ICI might be preferred for patients without peritoneal metastasis and irinotecan-based chemotherapy for patients with tumors without PD-L1 expression.
- Herceptin (trastuzumab) / Roche, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5042;
P1
ICI might be preferred for patients without peritoneal metastasis and irinotecan-based chemotherapy for patients with tumors without PD-L1 expression. Previously untx
- Xalkori (crizotinib) / Pfizer, Tagrisso (osimertinib) / AstraZeneca, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5029;
PDTOs response highly correlated with clinical response, especially for FOLFOX and FOLFIRI. The HTDS identified several novel therapeutic options for advanced GI cancer patients.
- Implementation of 3 month therapy for stage III colon cancer in a large community practice. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5003;
Of those that initiated therapy, 76% completed treatment. The results of the IDEA trial have influenced decision making for community oncologists.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Long-term follow-up results of ipilimumab and nivolumab for the treatment of mismatch repair deficient locally advanced rectal cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5002;
The use of ipi/nivo in this cohort of pts resulted in complete pathogenic responses for all that remain durable over an extended period of time, though with increased immune-related adverse events compared to anti-PD1 therapies alone. This regimen is currently being studied further in prospective studies.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical outcomes of patients who underwent total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): A single center experience. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4980;
In those patients who pursued surgical intervention, the pCR was lower than expected from trials. Patients who received FOLFOX tolerated treatment better with the same clinical response rate as CAPOX.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Adjuvant chemotherapy in ypStage III locally advanced rectal cancer after neoadjuvant treatment with an oxaliplatin-based regimen. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4978;
Among ypStage III LARC pateints after neoadjuvant treatment with Oxaliplatin-Based regimen, adjuvant chemotherapy with FOLFOX failed to improved surival benefit. More enhanced regimen might be necessary for these oxalipatin-resistant patients.
- Association of treatment regimens with quality of life and overall survival in patients with metastatic colorectal cancer in Peru. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4970;
Patients treated with FOLFOX as first line had better quality of life scores than those treated with FOLFIRI or capecitabine plus oxaliplatin, particularly in emotional and social/family well-being subscales. However, there was no significant difference in OS among the different treatment regimens.
- Avastin (bevacizumab) / Roche
A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4967;
P1
Enrollment and analysis are ongoing at D 140mg dose to confirm the RP2D to prevent OPIN in a future randomized phase II study. Clinical trial information: NCT04164069.
- 5-fluorouracil / Generic mfg.
Adjuvant chemotherapy after surgical resection of colorectal metachronous metastases: A phase II nonrandomized trial. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4954;
Patients older 18 years old and more with confirmed CRC and any site of resectable metachronous metastases were assigned to either surgery alone or adjuvant mFOLFOX6 for 6 months... ACT didn
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Proteomic profiling of FOLFOX-resistant colorectal cancer cells. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4948;
Proteomic profiling has found the cadherin binding as the significantly altered molecular process along with several important signalling pathways in chemoresistant CRC cells. These findings could suggest new directions in the development of anti-chemoresistance strategies of CRC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase II clinical trial of prior regimen rechallenge in third- or later-line treatment for patients with metastatic colorectal cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4944;
P2
For the patients with heavily treated mCRC, the re-application of chemotherapy with front-line treatment regimen has shown a decent effectiveness with acceptable safety. Clinical trial information: NCT03485027.
- Total neoadjuvant therapy for locally advanced rectal cancer: A western Australian experience. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4943;
TNT is a well-tolerated, effective and promising strategy for the management of LARC. Further data is needed to determine the standard TNT protocol.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
The multi-omics signature to predict sensitive to anti-epidermal growth factor receptor therapy in RAS wild-type colorectal cancer liver metastases. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4939;
P4
The multi-omics signature can serve as an intermediate surrogate marker of anti-EGFR treatment sensitivity and survival. The signature outperformed known biomarkers in providing an early prediction of treatment sensitivity and could be used to RAS wild type mCRC treatment decisions.
- 5-fluorouracil / Generic mfg.
Chemotherapy and radiofrequency hyperthermia (oncothermia) in the treatment of metastatic colorectal cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4932;
Despite the limitations of this observation, activity of this multi-modality treatment appears promising. Prospective randomized trials are needed to confirm these findings.
- Zelboraf (vemurafenib) / Roche
Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4929;
V+Co showed antitumor effects in CRC BRAF mutated patients who were heavily pre-treated. More randomized trials needed.
- Avastin (bevacizumab) / Roche
Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4928;
P1/2
The regimen was well tolerated. The study met its primary endpoint and support for future randomized phase III compared to standard of care.
- The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4885;
The results suggest that NKA dynamics within the first two cycles of treatment may hold relevant prognostic information in first-line treatment of mCRC. The possible causative relationship between NKA and treatment effect needs further elucidation, but calls for experimental trials combining chemotherapy with NK cell therapy in mCRC.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4853;
The possible causative relationship between NKA and treatment effect needs further elucidation, but calls for experimental trials combining chemotherapy with NK cell therapy in mCRC. Comprehensive genomic analysis could identify a significant number of HRD pancreatic cancer beyond germline BRCA1,2 and PALB2 mutation, and it would be helpful to choose the appropriate chemotherapy regimen.
- AMP945 / Amplia Therap
The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4823;
P1b/2a
The FAK inhibitor AMP945, given in a pulsed-dosing regimen in combination with FOLFIRINOX, significantly enhances survival in a mouse model of pancreatic cancer by increasing apoptosis and reducing tumor burden, highlighting the potential of this combination in clinical treatment of PC. A clinical study of the combination of AMP945 with FOLFIRINOX is now in planning.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer? () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4748;
32% of these mutations had NGS directed chemoimmunotherapy against these target mutations. In contrary to standard treatment regimens, a personalized treatment plan was developed for these patients, thereby curbing further progression & improving survival in patients with advanced cancer.
- pimurutamab (HLX07) / Fosun Pharma
Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4721;
P1/2
In contrary to standard treatment regimens, a personalized treatment plan was developed for these patients, thereby curbing further progression & improving survival in patients with advanced cancer. Three fixed-dose chemo-regimens were given together with HLX07: 1) gemcitabine 1000 mg/m2 (on Days 1 and 8) and cisplatin 75 mg/m2 (on Day 1) in 3-week cycles for 4
- STC-1010 / Brenus Pharma
Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4678;
A dose-escalation phase Ia (STC-1010 plus immunostimulant, associated to mFOLFOX6 w/o bevacizumab) will be performed with MSS mCRC patients to evaluate the safety and the recommended phase 2 trial dose (RP2D). A subsequent expansion phase IIa part will assess STC-1010 efficiency, associated with SoC in first-line setting for MSS patients, and in second-line setting after immunotherapy for MSI-H, dMMR or Lynch syndrome mCRC patients.
- Opdivo (nivolumab) / Ono Pharma, BMS
Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathologic study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4667;
From a diagnosis standpoint, Pathologists need to keep this entity in mind while working up tumors showing poorly differentiated to undifferentiated histology that are negative for most immunohistochemical markers. From clinical standpoint there is need to develop targeted therapy for this aggressive tumor.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Atezolizumab plus bevacizumab combined with transarterial embolization plus hepatic arterial infusion-chemotherapy for unresectable hepatocellular carcinoma with a diameter larger than 8 cm: A retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4647;
HAIC involved oxaliplatin, fluorouracil and leucovorin (FOLFOX regimen). Atezo-Bev combined with TAE and HAIC may be safe and effective for uHCC patients with high tumor burden, while further prospectively clinical research is necessary to validate the efficacy and safety.
- 5-fluorouracil / Generic mfg.
Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial. (On Demand | S404; Poster Bd # 387) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3755;
Future analyses will report quality of life and cost-effectiveness. Funding from NSW Government Dept of Health.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). (Live Stream | Hall B1) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3408;
P2/3
Patients and physicians have alternative strategies for management of LARC. Clinical trial information: NCT01515787.
- 5-fluorouracil / Generic mfg.
Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial. (Live Stream | Hall D2; Poster Bd # 219) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3169;
For pts with very low-lying cT3 LARC, NAC followed by TME and adjuvant chemotherapy achieved significantly better RFS and anus-preserving rates compared to upfront TME followed by adjuvant chemotherapy, without deteriorating postoperative complications or postoperative anal function. Clinical trial information: UMIN000009510.
- 5-fluorouracil / Generic mfg., floxuridine / Generic mfg.
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controlled trial. (Live Stream | Hall D2; Poster Bd # 216) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3165;
P3
However, patients with multiple liver metastases, RAS/BRAF mutation and those with positive postoperative ctDNA might benefit from adjuvant HAI treatment. Clinical trial information: NCT03500874.
- 5-fluorouracil / Generic mfg.
Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01). (Live Stream | Hall D2; Poster Bd # 215) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3164;
P2/3
This combined treatment should be considered as a valid option for these patients. Clinical trial information: NCT02494973.
- Vectibix (panitumumab) / Amgen, Takeda, Lumakras (sotorasib) / Amgen
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy. (Live Stream | Hall D2; Poster Bd # 213) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3161;
P1b/2
Adverse events were manageable and consistent with the expected safety profile of the drugs used, and there was no clinically meaningful Soto and irinotecan PK interaction. Clinical trial information: NCT04185883.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004. (On Demand | Hall A; Poster Bd # 332b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3159;
P2/3
U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG); Pfizer, Eli Lilly; Clinicaltrials.gov ID: NCT05710406. Clinical trial information: NCT05710406.
- 5-fluorouracil / Generic mfg.
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer (On Demand | Hall A; Poster Bd # 332a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3158;
P2
LCRT in both arms involves 4500 cGy in 25 fractions over 5 weeks (w) + 900 cGy boost in 5 fractions with a fluoropyrimidine (capecitabine preferred)...Support: U10CA180821, U10CA180882, U24 CA196171; https://acknowledgments.alliancefound.org. U10CA180868 (NRG); U10CA180888 (SWOG); Clinicaltrials.gov ID: NCT05610163 Clinical trial information: NCT05610163.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC) (On Demand | Hall A; Poster Bd # 330a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3154;
FOxTROT3 is assessing intensified NAC with modified FOLFOXIRI (mFOLFOXIRI; 5-fluorouracil, oxaliplatin, irinotecan) in fit pts...FOxTROT4: 6 wks NA encorafenib and cetuximab vs 6 wks OxFp NAC...Clinical trial information: ISRCTN83842641. >
- The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer. (On Demand | Hall A; Poster Bd # 329b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3153;
The primary objective for Phase IIa is to analyze the potential effect of FOLFOXIRI as an intensive adjuvant treatment for ctDNA clearance as a surrogate biomarker of treatment efficacy...Clinical trial information: 2021-000. 507-20.
- Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer. (Available On Demand; Poster Bd # 327b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3149;
P2, P3
Approximately 400 patients will be randomized 1:1 to the TUC experimental arm (TUC [300 mg orally twice daily] + Tras + mFOLFOX) or the SOC arm (mFOLFOX alone or in combination with either bevacizumab or cetuximab)...Enrollment is ongoing in North America, Asia, Australia, and Europe. Clinical trial information: NCT05253651.